Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Annaly Capital Management, Inc. (NLY) & American Capital Agency Corp. (AGNC)’s Analysis, Chimera Investment Corporation (CIM)’s Extension

Editor’s Note: Annaly Capital Management, Inc. (NYSE:NLY), American Capital Agency Corp. (NASDAQ:AGNC), Chimera Investment Corporation (NYSE:CIM), ARMOUR Residential REIT, Inc. (NYSE:ARR), Capstead Mortgage Corporation (NYSE:CMO)

Traders Recap – Annaly Capital Management, Inc. (NYSE:NLY), Staples, Inc. (NASDAQ:SPLS), Radian Group Inc (NYSE:RDN), Corning Incorporated (NYSE:GLW (SBWire)
Annaly Capital Management, Inc. (NYSE:NLY) started its trading session with the price of $11.65 and closed at $11.67 by scoring +0.09%. NLY’s stocks traded with total volume of 9.21 million shares, while the average trading remained 11.48 million shares. Annaly Capital Management, Inc. owns, manages, and finances a portfolio of real estate related investments in United States. The company invests in mortgage pass-through certificates, collateralized mortgage obligations, agency callable debentures.

Annaly Capital Management, Inc. (NYSE:NLY)

American Capital Agency’s Mid-Q3 2013 Book Value Projection And Derivative Portfolio Valuation Analysis – Part 3 (Seeking Alpha)
The focus of PART 3 of this article is to provide a mid-quarter update of American Capital Agency Corp. (NASDAQ:AGNC)’s third quarter of 2013 derivative portfolio regarding its valuation. I feel this mid-quarter update will provide readers a general direction on how the first-half of the third quarter of 2013 has panned out regarding AGNC’s overall hedging strategy. This article will focus on a detailed valuation analysis through 8/16/2013 regarding AGNC’s four main derivative instruments. In conjunction with AGNC’s derivative portfolio valuation analysis specific MBS prices, swap rates, and U.S. Treasury yields will be provided. This information will assist when projecting valuation amounts on American Capital Agency Corp. (NASDAQ:AGNC)’s derivative instruments as of 8/16/2013.

Chimera Investment Corporation Obtains New York Stock Exchange Listing Extension (EON: Enhanced Online News)
Chimera Investment Corporation (NYSE:CIM) announced today that it has received an extension for continued listing and trading of the Company’s stock on the New York Stock Exchange (NYSE). The extension granted by the NYSE, which is subject to review by the NYSE on an ongoing basis, provides the Company until January 31, 2014 to file its 2012 Annual Report on Form 10-K with the Securities and Exchange Commission. During the extension period, trading of the Company’s shares on the NYSE will remain unaffected.

Hot Stocks Alert (DCT Industrial Trust Inc. (NYSE:DCT), Inovio Pharmaceuticals Inc (NYSEMKT:INO), ARMOUR Residential REIT, Inc.(NYSE:ARR), Medical Properties Trust, Inc. (NYSE:MPW) (SBWire)
ARMOUR Residential REIT, Inc. (NYSE:ARR) shares fell 0.24% to $4.18. The company on August 27 announced that the Board of Directors has appointed Ms. Carolyn Downey as a new independent member of the Board of Directors of the Company, effective September 3, 2013. With the appointment of Ms. Downey, the Company expects to regain compliance with Section 303A.01 of the New York Stock Exchange Listed Company Manual and Section 802(a) of the NYSE MKT LLC Company Guide, both which require a majority of independent directors on the Company’s Board of Directors.

Zacks Upgrades Capstead Mortgage Corp. to Neutral (CMO) (Mideast Time)
Capstead Mortgage Corporation (NYSE:CMO) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research note issued on Monday, Stock Ratings Network.com reports. The firm currently has a $12.00 target price on the stock. Zacks‘ price objective suggests a potential upside of 2.21% from the company’s current price. A number of other analysts have also recently weighed in on CMO. Analysts at Compass Point cut their price target on shares of Capstead Mortgage Corporation (NYSE:CMO) from $14.00 to $13.50 in a research note to investors on Monday, July 29th. They now have a “buy” rating on the stock.

Loading...